PubRank

Constantine S Mitsiades

Author PubWeight™ 126.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011 14.34
2 Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010 4.52
3 Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011 4.46
4 Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002 4.33
5 The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2013 4.20
6 Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010 4.00
7 A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 3.89
8 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2002 3.73
9 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002 3.01
10 Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002 2.83
11 Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009 2.59
12 Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002 1.97
13 The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013 1.93
14 Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003 1.92
15 Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002 1.92
16 JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007 1.89
17 Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011 1.76
18 Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002 1.64
19 Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009 1.54
20 A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014 1.47
21 Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004 1.42
22 Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol 2004 1.39
23 Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012 1.36
24 FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005 1.32
25 Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003 1.28
26 Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011 1.26
27 FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005 1.25
28 Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011 1.23
29 CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002 1.23
30 Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A 2007 1.20
31 H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell 2012 1.19
32 Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003 1.15
33 Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009 1.09
34 Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J 2007 1.08
35 Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 2010 1.07
36 Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012 1.07
37 Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 2009 1.00
38 Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma 2009 1.00
39 Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012 0.99
40 Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011 0.98
41 Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol 2005 0.98
42 Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res 2013 0.96
43 Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One 2011 0.95
44 Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther 2012 0.94
45 Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013 0.94
46 Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009 0.93
47 Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 2013 0.92
48 Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 2009 0.92
49 Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009 0.91
50 Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood 2012 0.91
51 Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. Anticancer Res 2004 0.89
52 Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol 2012 0.89
53 Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk 2011 0.89
54 In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 2009 0.89
55 Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res 2010 0.89
56 The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 2013 0.89
57 Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol 2014 0.88
58 Concern Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. Am J Pathol 2002 0.88
59 Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer 2012 0.88
60 Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp. J Nat Prod 2012 0.86
61 Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002 0.86
62 Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 2011 0.85
63 Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica 2011 0.85
64 Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol 2012 0.85
65 Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012 0.84
66 Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol 2011 0.84
67 Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004 0.84
68 The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci 2007 0.83
69 Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci 2005 0.83
70 Novel therapies in myeloma. Curr Opin Hematol 2007 0.82
71 Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol 2012 0.82
72 Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am 2007 0.82
73 Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011 0.82
74 Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Invest Ophthalmol Vis Sci 2009 0.80
75 Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther 2012 0.80
76 Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol 2007 0.79
77 Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol 2013 0.79
78 High-throughput approaches to discover novel immunomodulatory agents for cancer. Oncoimmunology 2012 0.78
79 MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park) 2011 0.77
80 Bortezomib in the management of multiple myeloma. Cancer Manag Res 2009 0.77
81 Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2003 0.76
82 P2X7 polymorphism and chronic lymphocytic leukaemia. Lancet 2003 0.75
83 The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol 2011 0.75
84 Thyroid carcinoma cells and Fas-mediated apoptosis. Thyroid 2005 0.75
85 Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol 2006 0.75